Alcon Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumenta...
Latest News
12 days ago · seekingalpha.com
Alcon Sees Another Bullish Rating After Clear Portfolio Growth Direction In EyecareAlcon Inc. remains a Buy, supported by FDA approvals, portfolio-expanding acquisitions, and robust long-term eyecare demand despite recent market underperformance. ALC demonstrates steady revenue growth, improved core EPS guidance, and a pipeline of innovative products targeting high-need clinical niches like glaucoma and macular disease. Balance sheet strength is evident with investment-grade ratings and the lowest D/E ratio among peers, reducing leverage risk and enhancing the risk profile.
13 days ago · businesswire.com
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2GENEVA--(BUSINESS WIRE)--Alcon Acquires Neurotech and ENCELTO, the Only FDA Approved Treatment for MacTel Type 2.
13 days ago · globenewswire.com
Algoma Central Corporation Announces $62.5 million Offering of 6.20% Convertible Unsecured Subordinated DebenturesCATHARINES, ONTARIO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Algoma Central Corporation (“Algoma”) (TSX:ALC) announced today that it has entered into an agreement to sell, on a bought deal basis to a syndicate of underwriters led by CIBC Capital Markets, $50,000,000 aggregate principal amount of 6.20% convertible unsecured subordinated debentures (the “Debentures”) at a price of $1,000 per Debenture (the “Public Offering”).
17 days ago · businesswire.com
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking EyesGENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.
20 days ago · zacks.com
Credo Expands AI Connectivity Portfolio With 1.6T ZeroFlap ALCCRDO expands its AI connectivity portfolio with the 1.6T ZeroFlap Active Light Cable, offering lower power consumption, enhanced reliability and extended reach.
2 months ago · zacks.com
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?Alcon's acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.
2 months ago · seekingalpha.com
Alcon: A Re-Rating In EyesightAlcon is a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. At $72, ALC trades at ~18x forward earnings, reflecting mid-teens EPS growth but pricing in neither margin expansion nor pipeline optionality. Management targets 25% core operating margin by FY2027E, with current core EPS guidance raised to +12–15% growth and significant capital returns underway.
2 months ago · businesswire.com
Alcon Prices EUR 500 Million Senior Notes OfferingGENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500 Million Senior Notes Offering.
3 months ago · seekingalpha.com
Alcon: A Strong Company Trading Close To Its Intrinsic Value, BuyAlcon reported strong core operating profit (barring a one-time non-cash $402 million charge) during the quarter, up 17%. The company raised its full-year 2026 profit forecast for the second consecutive quarter. My DCF valuation states the stock is undervalued by 5.52%. I rate ALC a buy.
3 months ago · seekingalpha.com
Alcon Inc. (ALC) Q2 2026 Earnings Call TranscriptAlcon Inc. (ALC) Q2 2026 Earnings Call Transcript
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ALC